ANDA 74512, held by L. Perrigo. Clemastine Fumarate.
As of Nov 21, 2026, ANDA 74512 (Clemastine Fumarate), held by L. Perrigo, was first approved by FDA on Nov 22, 1995, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 22, 1995 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clemastine Fumarate1.34MG · tablet;oral | Clemastine Fumarate | Discontinued |
| Dec 13, 2002 | Supplement 7Manufacturing | Approved | None posted |
| Dec 13, 2002 | Supplement 8Manufacturing | Approved | None posted |
| Nov 21, 2002 | Supplement 6Labeling | Approved | None posted |
| Mar 23, 2001 | Supplement 4Manufacturing | Approved | None posted |
| Mar 23, 2001 | Supplement 5Manufacturing | Approved | None posted |
| Jan 27, 2000 | Supplement 3Labeling | Approved | None posted |
| Jul 9, 1997 | Supplement 1Manufacturing | Approved | None posted |
| Jul 9, 1997 | Supplement 2Manufacturing | Approved | None posted |
| Nov 22, 1995 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters